121564-97-4

Basic information

• Product Name: 6-BROMO-8-METHYL-4H-BENZO[1,4]OXAZIN-3-ONE
• Synonyms: 6-BROMO-8-METHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE;6-BROMO-8-METHYL-4H-BENZO[1,4]OXAZIN-3-ONE;6-broMo-8-Methyl-3,4-dihydro-2H-1,4-benzoxazin-3-one;6-broMo-8-Methyl-2H-1,4-Benzoxazin-3(4H)-one;6-bromo-8-methyl-4H-1,4-benzoxazin-3-one
• CAS NO: 121564-97-4
• Molecular Formula: C₉H₈BrNO₂
• Molecular Weight: 242.07
• Mol File: 121564-97-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-BROMO-8-METHYL-4H-BENZO[1,4]OXAZIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-8-METHYL-4H-BENZO[1,4]OXAZIN-3-ONE(121564-97-4)
• EPA Substance Registry System: 6-BROMO-8-METHYL-4H-BENZO[1,4]OXAZIN-3-ONE(121564-97-4)

Safety Data

• Hazardous Substances Data: 121564-97-4(Hazardous Substances Data)

Usage

General Description

6-BROMO-8-METHYL-4H-BENZO[1,4]OXAZIN-3-ONE (CAS 100724-38-2) is a chemical compound with the molecular formula C9H6BrNO2. It is a brominated oxazine derivative and belongs to the benzoxazine class of compounds. This chemical is primarily used in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and as a building block for the synthesis of other complex organic compounds. Additionally, it may be used in the production of specialty chemicals and materials. However, due to its potential reactivity and toxicity, proper handling and storage procedures should be followed when working with this compound.

Upstream product

• 20294-50-2 4-bromo-2-methyl-6-nitrophenol 
• 79-07-2 Chloroacetamide 
• 943994-74-9 methyl (4-bromo-2-methyl-6-nitrophenoxy)acetate 

Downstream Products

• 102065-94-1 8-methyl-4H-benz[1,4]oxazin-3-one 
• 1221500-65-7 6-[5-(4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]-8-methyl-2H-1,4-benzoxazin-3(4H)-one 
• 943994-87-4 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-1,4-benzoxazin-3(4H)-one 
• 121565-03-5 (6-Bromo-8-methyl-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-acetic acid ethyl ester 

Relevant articles and documents

Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists

In the course of our study on selective nonsteroidal mineralocorticoid receptor (MR) antagonists, a series of novel benzoxazine derivatives possessing an azole ring as the core scaffold was designed for the purpose of attenuating the partial agonistic activity of the previously reported dihydropyrrol-2-one derivatives. Screening of alternative azole rings identified 1,3-dimethyl pyrazole 6a as a lead compound with reduced partial agonistic activity. Subsequent replacement of the 1-methyl group of the pyrazole ring with larger lipophilic side chains or polar side chains targeting Arg817 and Gln776 increased MR binding activity while maintaining the agonistic response at the lower level. Among these compounds, 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (37a) showed highly potent in vitro activity, high selectivity versus other steroid hormone receptors, and good pharmacokinetic profiles. Oral administration of 37a in deoxycorticosterone acetate-salt hypertensive rats showed a significant blood pressure-lowering effect with no signs of antiandrogenic effects.

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.